Gene · 3818
KLKB1: kallikrein B1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. KLKB1: kallikrein B1. Genes, record 3818. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3818
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P03952 | Plasma kallikrein | 638 | 22 | Ensembl, GeneID, HGNC |
Source UniProt
Patents120
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026048915 A | 2026-03-17 | 3 | P03952 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 50532 | P03952 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 2384 | P03952 | Espacenet |
| US 12460016 B2 | 2025-11-04 | 2 | P03952 | Espacenet |
| EP 4640849 A2 | 2025-10-29 | 283 | P03952 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 1960 | P03952 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 7585 | P03952 | Espacenet |
| JP 2025519096 A | 2025-06-24 | 283 | P03952 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 1960 | P03952 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 2384 | P03952 | Espacenet |
1 to 10 of 120
See all 120 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| APROTININ | CHEMBL1201619 | Plasma kallikrein inhibitor | INHIBITOR | ChEMBL |
| AVORALSTAT | CHEMBL4297502 | Plasma kallikrein inhibitor | INHIBITOR | ChEMBL |
| BEROTRALSTAT | CHEMBL5189739 | Plasma kallikrein inhibitor | INHIBITOR | ChEMBL |
| BEROTRALSTAT HYDROCHLORIDE | CHEMBL6067995 | Plasma kallikrein inhibitor | INHIBITOR | ChEMBL |
| ECALLANTIDE | CHEMBL1201837 | Plasma kallikrein inhibitor | INHIBITOR | ChEMBL |
| HUMAN C1-ESTERASE INHIBITOR | CHEMBL4297549 | Plasma kallikrein inhibitor | INHIBITOR | ChEMBL |
| LANADELUMAB | CHEMBL3545189 | Plasma kallikrein inhibitor | INHIBITOR | ChEMBL |
Trials32
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07317050 | APROTININ | PHASE3 | ClinicalTrials.gov | |
| NCT07228559 | AVORALSTAT | PHASE1 | ClinicalTrials.gov | |
| NCT05460325 | LANADELUMAB | PHASE3 | 2024-12-13 | ClinicalTrials.gov |
| NCT05397431 | LANADELUMAB | ClinicalTrials.gov | ||
| NCT04933721 | BEROTRALSTAT | PHASE3 | ClinicalTrials.gov | |
| NCT04848272 | LANADELUMAB | PHASE1 | ClinicalTrials.gov | |
| NCT04590586 | LANADELUMAB | PHASE3 | 2022-06-29 | ClinicalTrials.gov |
| NCT04527133 | APROTININ | ClinicalTrials.gov | ||
| NCT04460105 | LANADELUMAB | PHASE1 | ClinicalTrials.gov | |
| NCT04422509 | LANADELUMAB | PHASE1/PHASE2 | ClinicalTrials.gov |
1 to 10 of 32
See all 32 trialsNIH grants1,110
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | KLKB1 papers | Newest fiscal year |
|---|---|---|---|
| P30DK036836 | Diabetes Research Center | 12 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 6 | 2025 |
| R01HL144113 | Contact Pathway Activation on Vascular Devices | 6 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 4 | 2025 |
| R01HL086694 | From GWAS loci to blood pressure genes, variants & mechanisms - Renewal | 4 | 2025 |
| R01HL101972 | Characterization of Coagulation Factor-platelet Interactions: Role of FXI | 4 | 2025 |
| ZIABC010348 | Protein Structure | 4 | 2025 |
| ZIAHL006001 | Framingham Project/Levy | 4 | 2025 |
| P20GM103424 | Louisiana Biomedical Research Network | 3 | 2025 |
| P41GM108538 | National Center for Quantitative Biology of Complex Systems | 3 | 2025 |
1 to 10 of 1,110Source NIH's project files
See all 1,110 nih grantsPapers2,245
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Phosphorus recovery from phosphogypsum by Bacillus altitudinis. | Bioresour Technol | 2026 | 42785692 | PubTator, text mining | PubMed |
| Trypsin is as procoagulant as factor XIIa. | Bleeding Thromb Vasc Biol | 2026 | 42712886 | PubTator, text mining | PubMed |
| Proteomic Pathways Linking Type 2 Diabetes Genetic Clusters to Cardiovascular Diseases: A Network Mendelian Randomisation Study. | Diabetes Obes Metab | 2026 | 42638160 | PubTator, text mining | PubMed |
| Lonvoguran ziclumeran: a CRISPR-CAS9-based gene therapy for the treatment of hereditary angioedema. | Expert Opin Investig Drugs | 2026 | 42504735 | PubTator, text mining | PubMed |
| Genetic architecture and cross-platform validation of apolipoprotein A-IV concentrations. | Genome Biol | 2026 | 42449406 | PubTator, text mining | PubMed |
| Deep Proteomic Analysis With Machine Learning Identifies Aqueous Humor Biomarkers of ADAMTSL4-associated Congenital Ectopia Lentis. | Invest Ophthalmol Vis Sci | 2026 | 42423409 | PubTator, text mining | PubMed |
| Mapping tissue-specific protease dynamics in the pig respiratory tract during influenza a virus infection. | Sci Rep | 2026 | 42414375 | PubTator, text mining | PubMed |
| Microbial Life-History Strategies and Functional Gene Regulation Drive Soil Nitrogen and Phosphorus Bioavailability During Succession in an Arid Valley Ecosystem. | Mol Ecol | 2026 | 42175735 | PubTator, text mining | PubMed |
| Kallikrein-8 contributes to kallikrein-kinin system dysregulation in Alzheimer's disease. | Exp Neurol | 2026 | 42140379 | PubTator, text mining | PubMed |
| Lanadelumab safety, efficacy, and pharmacokinetics in patients aged ≥12 with hereditary angioedema in China: an open-label, multicenter study. | Front Immunol | 2026 | 42136633 | PubTator, text mining | PubMed |
1 to 10 of 2,245
See all 2,245 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3818
GET https://conductscience.org/api/genes/v1/3818/patents?page=2